Officials with the U.S. Army Medical Research Institute of Infectious Diseases and AVI BioPharma announced that they have created a drug that showed effectiveness in combating the Marburg and Ebola viruses.
The U.S. Department of Defense Chemical and Biological Defense Program, part of the U.S. Army Space and Missile Defense Command, has awarded AVI BioPharma, Inc., a new contract for the development of Marburg and Ebola virus therapeutic candidates.
The National Institute of Health announced that a drug supported by the federal agency has shown it is capable of preventing outbreaks of Marbug hemorrhagic fever - similar to the Ebola virus - in test monkeys.
Dutch pharmaceutical firm Crucell has awarded a significant contract to Southwest Foundation for Biomedical Research to develop a vaccine for potential bioterror weapons Ebola and Marburg.
Federal stimulus money has been granted to the New England Primate Research Center for investigations and a contract tied to developing a vaccine for the Marburg and Ebola viruses.
